{"id":"antipsychotic-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Extrapyramidal symptoms (EPS)"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Metabolic syndrome"},{"rate":null,"effect":"Hyperprolactinemia"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antipsychotics typically block dopamine D2 receptors and/or serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical pathways associated with psychosis. This mechanism helps alleviate positive symptoms such as hallucinations and delusions, and some agents also improve negative symptoms and cognitive dysfunction.","oneSentence":"Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:01.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"},{"name":"Psychotic disorders"}]},"trialDetails":[{"nctId":"NCT07130500","phase":"NA","title":"Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2026-03-09","conditions":"Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD)","enrollment":1000},{"nctId":"NCT06687694","phase":"","title":"Immune Mechanisms of Antipsychotic Treatment Response","status":"RECRUITING","sponsor":"King's College London","startDate":"2025-08-06","conditions":"Psychosis","enrollment":500},{"nctId":"NCT06474195","phase":"NA","title":"Cue-based Intervention in Prospective Memory and Medication Adherence.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-06-15","conditions":"Schizophrenia","enrollment":104},{"nctId":"NCT07483294","phase":"","title":"Cerebellum-based Imaging Neural Markers for Antipsychotic Response","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-01","conditions":"Psychosis; Acute","enrollment":120},{"nctId":"NCT06580860","phase":"","title":"Psychiatric Multi-omics and Neuroimaging Project","status":"RECRUITING","sponsor":"mingjun Zhong","startDate":"2016-01","conditions":"Mental Disorders, Healthy Control","enrollment":1899},{"nctId":"NCT07448675","phase":"","title":"Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Anding Hospital","startDate":"2023-02-07","conditions":"Patients With Severe Mental Illness","enrollment":230},{"nctId":"NCT07445802","phase":"NA","title":"Medication Adherence in Severe Mental Illness: a Promotion Program","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2026-09","conditions":"Treatment Adherence and Compliance, Severe Mental Disorders, Bipolar Disorder (BD)","enrollment":1640},{"nctId":"NCT07446218","phase":"NA","title":"Pharmacist-led Interventions in Psychiatric Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Lahore","startDate":"2026-03-01","conditions":"Mental Disorders, Metabolic Syndrome","enrollment":148},{"nctId":"NCT07445217","phase":"PHASE2","title":"Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia","status":"COMPLETED","sponsor":"Calo Psychiatric Center","startDate":"2008-03-10","conditions":"Functional Outcomes","enrollment":763},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT07432763","phase":"NA","title":"Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia","status":"COMPLETED","sponsor":"Panhellenic Federation of Alzheimer's Disease and Related Disorders","startDate":"2024-05-01","conditions":"Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent, Antipsychotics Discontinuation","enrollment":18},{"nctId":"NCT05356013","phase":"PHASE2","title":"Caplyta in Borderline Personality Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2023-05-10","conditions":"Borderline Personality Disorder","enrollment":60},{"nctId":"NCT06410508","phase":"NA","title":"Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2024-09-01","conditions":"Psychotic Disorders, Psychiatric Hospitalization, Engagement, Patient","enrollment":40},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT05110157","phase":"PHASE3","title":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-29","conditions":"Schizophrenia","enrollment":442},{"nctId":"NCT07386483","phase":"NA","title":"Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University College Dublin","startDate":"2026-02-01","conditions":"Psychosis","enrollment":40},{"nctId":"NCT00183625","phase":"PHASE4","title":"Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2000-06","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT04860830","phase":"PHASE3","title":"CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-09","conditions":"Schizophrenia","enrollment":609},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder","enrollment":524},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT05662306","phase":"PHASE4","title":"C-Cog in Early Course Schizophrenia Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2024-01-23","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT06456983","phase":"NA","title":"Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-02-14","conditions":"Schizophrenia, Treatment Resistant Schizophrenia","enrollment":140},{"nctId":"NCT07184619","phase":"PHASE3","title":"Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia","status":"RECRUITING","sponsor":"Newron Pharmaceuticals SPA","startDate":"2026-01-23","conditions":"Treatment-resistant Schizophrenia","enrollment":400},{"nctId":"NCT07371325","phase":"NA","title":"Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Manuel Jesús Cuesta Zurita","startDate":"2024-09-08","conditions":"SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement","enrollment":36},{"nctId":"NCT07356765","phase":"NA","title":"Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Anding Hospital","startDate":"2023-09-26","conditions":"Schizophrenia, Negative Symptoms of Schizophrenia","enrollment":120},{"nctId":"NCT05208190","phase":"PHASE4","title":"Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-17","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":280},{"nctId":"NCT07363577","phase":"PHASE3","title":"Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-03","conditions":"Schizophrenia","enrollment":456},{"nctId":"NCT04370730","phase":"NA","title":"Dimensional and Developmental Profiles of Psychosis in Children and Adolescents","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-02","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT07351240","phase":"NA","title":"The Acupuncture Treatment Effect in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calo Psychiatric Center","startDate":"2025-12-16","conditions":"Mental Health","enrollment":100},{"nctId":"NCT07360665","phase":"NA","title":"Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics","status":"RECRUITING","sponsor":"University of Trás-os-Montes and Alto Douro","startDate":"2026-01-01","conditions":"Psychotic Disorders, Schizophrenia Spectrum Disorders (SSD), Severe Mental Illness","enrollment":44},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05528224","phase":"NA","title":"Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial","status":"TERMINATED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":46},{"nctId":"NCT06869187","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2025-03-28","conditions":"Bipolar Disorder Depression","enrollment":35},{"nctId":"NCT07162467","phase":"","title":"Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Anding Hospital","startDate":"2024-02-19","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT03442101","phase":"","title":"Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-01","conditions":"Psychosis","enrollment":156},{"nctId":"NCT06624462","phase":"NA","title":"Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2023-10-10","conditions":"Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication","enrollment":84},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT01626872","phase":"PHASE2, PHASE3","title":"Long-Term Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-09","conditions":"Schizophrenia","enrollment":254},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05939765","phase":"","title":"Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.","status":"WITHDRAWN","sponsor":"Psychiatric University Hospital, Zurich","startDate":"2025-12-01","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT07252752","phase":"NA","title":"Dopamine and Insulin in Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-01","conditions":"First Episode Psychosis (FEP)","enrollment":46},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT07246044","phase":"NA","title":"HD-tDCS for Adolescent Bipolar Depression Targeting S1","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-09-16","conditions":"Adolescent, Bipolar Depression, tDCS","enrollment":100},{"nctId":"NCT01543321","phase":"PHASE3","title":"Xenazine in Late Dyskinetic Syndrome With Neuroleptics","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-14","conditions":"Tardive Dyskinesia","enrollment":54},{"nctId":"NCT06831942","phase":"NA","title":"Attempted Suicide Short Intervention Program for Older Adults (ASSIP-OA): An Evaluation of a Psychosocial Intervention for Suicidal Adults Aged 65+","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-10-01","conditions":"Suicidal Ideation, Suicide Attempt, Suicide","enrollment":132},{"nctId":"NCT06221852","phase":"NA","title":"Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder","status":"RECRUITING","sponsor":"Mclean Hospital","startDate":"2024-03-12","conditions":"Bipolar I Disorder, Psychosis, Schizoaffective Disorder","enrollment":50},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT06067984","phase":"PHASE3","title":"An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-09-12","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia","enrollment":73},{"nctId":"NCT05838625","phase":"PHASE3","title":"Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-03-31","conditions":"Schizophrenia","enrollment":464},{"nctId":"NCT07206563","phase":"PHASE1, PHASE2","title":"Penfluridol for Relapsed/Refractory Small Cell Cancers","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-10-01","conditions":"Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC )","enrollment":33},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT07085923","phase":"NA","title":"Norwegian Mental Illness Heart Health Study","status":"RECRUITING","sponsor":"Madeleine Elisabeth Angelsen","startDate":"2025-09-16","conditions":"Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder","enrollment":70},{"nctId":"NCT07075237","phase":"PHASE4","title":"Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-10","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT05958875","phase":"PHASE4","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-01","conditions":"Schizophrenia and Related Disorders, Early Treatment-Resistance","enrollment":418},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT05590637","phase":"PHASE4","title":"Comparing Antipsychotic Medications in LBD Over Time","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-04-22","conditions":"Parkinson's Disease Psychosis, Dementia With Lewy Bodies","enrollment":94},{"nctId":"NCT07153835","phase":"PHASE4","title":"Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study","status":"NOT_YET_RECRUITING","sponsor":"Sher-E-Bangla Medical College","startDate":"2025-09-01","conditions":"Schizophrenia","enrollment":505},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT03121586","phase":"PHASE3","title":"Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2017-01","conditions":"Schizophrenia","enrollment":995},{"nctId":"NCT04531982","phase":"PHASE3","title":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2020-08-05","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT07134816","phase":"NA","title":"Cost-utility Study of Cognitive-behavioral Management of Auditory Hallucinations in Schizophrenic Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-08","conditions":"Auditory Hallucinations, Schizophrenia Spectrum","enrollment":240},{"nctId":"NCT06904079","phase":"NA","title":"Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2024-03-12","conditions":"Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder","enrollment":82},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT07122531","phase":"NA","title":"Recovery With Exogenous Ketones and Antipsychotics","status":"NOT_YET_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08-25","conditions":"First Episode Psychosis","enrollment":15},{"nctId":"NCT07102069","phase":"","title":"Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Tianjin Anding Hospital","startDate":"2017-11-01","conditions":"Schizophrenia","enrollment":384},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT07086040","phase":"NA","title":"Effects of RAS in SZ","status":"NOT_YET_RECRUITING","sponsor":"Shu-Mei Wang","startDate":"2025-08-01","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":140},{"nctId":"NCT01825798","phase":"PHASE3","title":"Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)","status":"COMPLETED","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2013-04","conditions":"Overweight, Autism Spectrum Disorder","enrollment":60},{"nctId":"NCT04761861","phase":"PHASE2","title":"Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-16","conditions":"Schizophrenia, Dyslipidemias","enrollment":""},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT07055204","phase":"NA","title":"Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-01-04","conditions":"Schizophrenia Disorders","enrollment":120},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":"Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug","enrollment":88},{"nctId":"NCT06949657","phase":"NA","title":"Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and","status":"TERMINATED","sponsor":"Third People's Hospital, Huzhou City, Zhejiang Province, China","startDate":"2023-10-13","conditions":"Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy","enrollment":78},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT07011953","phase":"EARLY_PHASE1","title":"A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-07-01","conditions":"Schizophrenia, Avolition","enrollment":90},{"nctId":"NCT07001878","phase":"PHASE4","title":"Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2025-07-01","conditions":"Psychosis, Cannabis Use","enrollment":24},{"nctId":"NCT03526354","phase":"PHASE4","title":"Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2018-06-19","conditions":"Schizophrenia, Schizoaffective Disorder, Substance Use Disorders","enrollment":50},{"nctId":"NCT06978803","phase":"","title":"HYEEG Discourse in Psychosis: A Neurobehavioural Study","status":"RECRUITING","sponsor":"Douglas Mental Health University Institute","startDate":"2024-01-16","conditions":"Psychosis, Schizophrenia Disorders","enrollment":110},{"nctId":"NCT06754163","phase":"PHASE4","title":"Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","status":"RECRUITING","sponsor":"St Andrew's Healthcare","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Psychiatric Disorders","enrollment":20},{"nctId":"NCT03351244","phase":"PHASE2","title":"This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-07","conditions":"Schizophrenia","enrollment":264},{"nctId":"NCT06245213","phase":"PHASE2","title":"A Study of ANAVEX3-71 in Adults With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anavex Life Sciences Corp.","startDate":"2024-03-15","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT06136936","phase":"NA","title":"A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-09-20","conditions":"Schizophrenia","enrollment":53},{"nctId":"NCT05461885","phase":"NA","title":"Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-10-25","conditions":"Affective Disorder, Psychosis","enrollment":400},{"nctId":"NCT06453174","phase":"","title":"CLinical Utility of Early Intervention Including the 5-Step Precision Medicine (5SPM) Method in First-episode Psychosis: The CLUMP Project","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2024-01-01","conditions":"Psychosis","enrollment":300},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT05667961","phase":"","title":"Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-15","conditions":"Schizophrenia","enrollment":480},{"nctId":"NCT06936137","phase":"PHASE3","title":": EFFECT OF PROBIOTIC SUPPLEMENTATION ON ATYPICAL ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS ATTENDING PSYCHIATRIC CLINICS AT AINSHAMS UNIVERSITY HOSPITALS (A RANDOMIZED CONTROLLED TRIAL)","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-04-20","conditions":"Antipsychotic Induced Weight Gain","enrollment":180},{"nctId":"NCT06558201","phase":"NA","title":"Open Label Extension Study of NCT06221852","status":"ENROLLING_BY_INVITATION","sponsor":"Mclean Hospital","startDate":"2024-08-28","conditions":"Bipolar I Disorder, Schizoaffective Disorder, Psychosis","enrollment":50},{"nctId":"NCT06451952","phase":"NA","title":"Virtual Darkness Theraphy for Agitation in Dementia","status":"RECRUITING","sponsor":"University of Bergen","startDate":"2024-09-30","conditions":"Agitation in Dementia, Including Alzheimer's Disease","enrollment":72},{"nctId":"NCT06924255","phase":"PHASE4","title":"An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Collaborative Neuroscience Research, LLC","startDate":"2025-04","conditions":"Schizophrenia Disorders","enrollment":100},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4481,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antipsychotic drugs"],"phase":"phase_3","status":"active","brandName":"Antipsychotic treatment","genericName":"Antipsychotic treatment","companyName":"Fundación Pública Andaluza Progreso y Salud","companyId":"fundaci-n-p-blica-andaluza-progreso-y-salud","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms. Used for Schizophrenia, Bipolar disorder, Psychotic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}